An article from
News roundup
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Alumis is discarding a once-highly touted immune drug.
Published May 15, 2026
Getty Images
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.
An article from
News roundup
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Alumis is discarding a once-highly touted immune drug.
Published May 15, 2026
Getty Images

Biopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?

Biopharma industry endorses Pazdur for FDA commissioner role - Pharmaceutical Technology

Takeda, slimming down for 'new era,' plots 4,500 layoffs in latest restructuring drive

Astellas treatment offers new hope to a devastated rare disease community

AstraZeneca picks up FDA approval for hypertension drug

Pharma leaders hope next FDA head calms waters

FDA shuffles top drug, biologics leaders in latest shakeup

After Makary departure, CDER chief Tracy Beth Høeg likely headed out at FDA: report

With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across…

Hundreds of biopharma leaders say Dr Richard Pazdur has the necessary qualities to lead the FDA amid a crisis of confidence.

With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake…

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron…

With China's growing dominance in the biopharma R&D sector, a collection of g | A group of over 20 global pharma leaders met with…

Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout